肾康网 > 利妥昔单抗 Rituximab英语短句例句大全

利妥昔单抗 Rituximab英语短句例句大全

时间：2020-11-06 09:09:07

相关推荐

利妥昔单抗,Rituximab

1)Rituximab利妥昔单抗

1.Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin s lymphoma;利妥昔单抗对于非霍奇金淋巴瘤的治疗及其药物经济学

2.Rituximab in Combination with CHOP Scheme for Non-Hodgkin s Lymphoma: Evaluation of Clinical Efficacy;利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价

3.Expression of CD16ζ in NK Cells of B-cell Non-Hodgkin s Lymphoma Patients and In Vitro Killing Effect ofRituximab Combined Lymphokine-activated Killer Cells on B-NHL Cells;B-NHL患者NK细胞中CD16ζ表达及利妥昔单抗与LAK细胞的联合抗瘤作用

英文短句/例句

1.The nursing experience of rituximab in combined with chemotherapy in elderly patient with non-hodgkin s lymphoma;利妥昔单抗治疗老年非霍奇金淋巴瘤护理体会

2.Treatment of B-cell Lymphoma with the Regimen of Rituximab Combined Chemotherapy利妥昔单抗联合化疗方案治疗B细胞淋巴瘤

3.Systematic Review of Maintenance Rituximab Therapy in B Cell Non-Hodgkin Lymphoma利妥昔单抗维持治疗B细胞非霍奇金淋巴瘤的系统评价

4.Clinic observation with diffuse large B-cell lymphoma treated by combination of rituximab and CHOP利妥昔单抗联合CHOP方案治疗弥漫性大B细胞淋巴瘤临床观察

5.Efficacy of rituximab in patients with refractory severe systemic lupus erythematosus利妥昔单抗治疗难治性重症系统性红斑狼疮的临床初步观察

6.Treatment of Immunorelated pancytopenia with regimen of rituximab and chemotherapy:a case report利妥昔单抗联合化疗治疗免疫相关性全血细胞减少症1例

7.Rituximab therapy for rheumatoid arthritis利妥昔单抗治疗类风湿性关节炎基础研究临床应用现状及展望

8.Clinical observation of effect of rituximab combined with chemotherapy on non-Hodgkin"s lymphoma利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的临床观察

9.Use of Rituximab in Infant Childhood Immune Thrombocytopenic Purpura Who Useless with Routine Treatment利妥昔单抗治疗婴幼儿常规治疗无效的特发性血小板减少性紫癜

10.Clinical observation on rituximab combined with chemotherapy in the treatment of diffused large B cell lymphoma利妥昔单抗联合化疗治疗弥漫型大B细胞淋巴瘤的临床观察

11.Rituximab combination with CHOP treated primary breast non-Hodgkin lymphoma:one case report and leterature review利妥昔单抗联合CHOP方案治疗原发性乳腺非霍奇金淋巴瘤1例并文献复习

12.Nursing Care for Patients with B-Cell Non-Hodgkin"s Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation Combined with Rituximab2例B细胞非霍奇金淋巴瘤患者异基因造血干细胞移植联合利妥昔单抗治疗的护理

13.A Clinical Study of Rituximab Combined with CHOP in Treatment of B Cell Non-Hodgkins Lymphoma利妥昔单抗联合CHOP治疗弥漫大B细胞性非霍奇金淋巴瘤的临床观察

14.Bacterial Endotoxin Test of Cetuximab Injection西妥昔单抗注射液细菌内毒素检查法

15.A experimental study on inhibiting effect of cetuximab on angiogenesis西妥昔单抗抑制血管生成的实验研究

16.Cetuximab plus chemotherapy in the treatment of patients with head and neck squamous cell carcinomas (HNSCC)西妥昔单抗联合化疗治疗头颈部鳞癌初步研究

17.Protection of ward of liver cancer patients after undergoing ~(131)I rituximab intervention therapy~(131)碘美妥昔单抗介入治疗肝癌术后病室的防护

18.Cetuximab for the treatment of metastatic colorectal cancer:a meta-analysis西妥昔单抗治疗转移性结直肠癌的荟萃分析

相关短句/例句

rituximab利妥昔单克隆抗体

1.In order to evaluate the effecicney ofrituximab combined with fludarabine,cyclophosphamide andrituximab(FCR) regimen for chronic lymphocytic leukemia(CLL).为了探讨利妥昔单克隆抗体联合氟达拉滨及环磷酰胺(FCR方案)治疗慢性淋巴细胞白血病(CLL)的疗效,采用FCR方案(2-6个疗程)治疗5例CLL患者,其中2例初治、3例复治。

2.The aim of this study was to compare the efficacy ofrituximab plus CHOP regimen and CHOP regimen on newly diagnosed patients with diffuse large B-cell lymphoma(DLBCL),and analyze their toxicities.为比较利妥昔单克隆抗体联合标准CHOP方案与标准CHOP方案治疗初治CD20阳性的弥漫慢大B细胞淋巴瘤(DLBCL)患者的疗效和安全性,采用同期(7月至12月)非随机对照的前瞻性研究方法,将69例在我院住院的初治DLBCL患者分为R-CHOP组和CHOP组,其中CHOP组36例,R-CHOP组33例,比较两组的完全缓解率、生存期及不良反应情况。

3)Cetuximab西妥昔单抗

1.Evaluation ofCetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck;西妥昔单抗联合化疗或放疗治疗晚期头颈鳞癌的疗效评价(英文)

2.Effects ofCetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402;西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用

3.Clinical observation of combination chemotherapy for metastatic colorectal cancer withCetuximab;西妥昔单抗联合化疗治疗转移性结直肠癌的临床观察

4)Cetuximab(C225)西妥昔单抗(C225)

5)infliximab英利昔单抗

1.Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomized,double blind,controlled trial;英利昔单抗联合甲氨蝶呤治疗类风湿关节炎的随机双盲临床研究

2.Methods: A retrospective analysis of incidence rate of adverse events(AE),serious adverse events(SAE) and laboratory test abnormal outcomes was conducted for patients with AS who were treated withinfliximab and etanercept according to WHOART systematic classification by World Health Organization.方法:对应用英利昔单抗(infliximab)和依那西普(etanercept)治疗期间及随访过程中AS患者所发生的全部不良事件、严重不良事件、实验室检查等进行总结分析,根据世界卫生组织不良反应术语命名(WHOART)系统进行分类,观察不良事件的发生情况。

3.OBJECTIVE:To evaluate the efficacy and the safety ofinfliximab for the treatment of the diseases of digestive system.目的:评价英利昔单抗在消化系统相关疾病治疗中的疗效和安全性。

6)Basiliximab巴利昔单抗

1.Application of basiliximab in prevention of acute allograft rejection in kidney transplantation recipients;巴利昔单抗在预防肾移植后排斥反应中的应用

2.Influence of basiliximab and on recipients interleukin-2 and soluble interleukin-2 receptor after renal transplantation;巴利昔单抗对肾移植受者白细胞介素2和可溶性白介素2受体的影响

3.Meta-analysis of the effect of basiliximab on renal graft rejection and survival巴利昔单抗对肾移植排斥反应及移植物存活影响的Meta分析